title: Fingolimod does not enhance cerebellar remyelination in the cuprizone model.
abstract: Fingolimod (FTY720) is approved for treatment of relapsing-remitting multiple sclerosis. In vitro studies have found that fingolimod stimulates remyelination in cerebellar slices, but in vivo animal studies have not detected any positive effect on cerebral remyelination. The discrepant findings could be a result of different mechanisms underlying cerebral and cerebellar remyelination. The cuprizone model for de- and remyelination was used to evaluate whether fingolimod had an impact on cerebellar remyelination in vivo. We found that fingolimod did not have any effect on cerebellar remyelination, number of mature oligodendrocytes, microglia or astrocytes when fed after cuprizone exposure.
authors.affiliation: Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: maria.alme@uib.no.
authors.forename: Maria Nordheim
authors.initials: MN
authors.lastname: Alme
authors.affiliation: Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway; Kristian Gerhard Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: Agnes.elisabeth.nystad@helse-bergen.no.
authors.forename: Agnes E
authors.initials: AE
authors.lastname: Nystad
authors.affiliation: Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway; Kristian Gerhard Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: lars.bo@helse-bergen.no.
authors.forename: Lars
authors.initials: L
authors.lastname: Bø
authors.affiliation: Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway; Kristian Gerhard Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: kjell-morten.myhr@helse-bergen.no.
authors.forename: Kjell-Morten
authors.initials: KM
authors.lastname: Myhr
authors.affiliation: Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway; Kristian Gerhard Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway; Department of Neurology, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway. Electronic address: christian.alexander.vedeler@helse-bergen.no.
authors.forename: Christian A
authors.initials: CA
authors.lastname: Vedeler
authors.affiliation: Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway; Kristian Gerhard Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: stig.wergeland@helse-bergen.no.
authors.forename: Stig
authors.initials: S
authors.lastname: Wergeland
authors.affiliation: Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Haukelandsveien 22, 5021 Bergen, Norway; Kristian Gerhard Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: oivind.torkildsen@helse-bergen.no.
authors.forename: Øivind
authors.initials: Ø
authors.lastname: Torkildsen
mesh_terms: D000818:Animals; D002531:Cerebellum / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D003471:Cuprizone / Q000633:toxicity*; D003711:Demyelinating Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology; D004195:Disease Models, Animal; D005260:Female; D000068876:Fingolimod Hydrochloride; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D011409:Propylene Glycols / Q000627:therapeutic use*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D003471:Cuprizone; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine
keywords: Cerebellum; Cuprizone; Demyelination; FTY720; Fingolimod; Remyelination